EMAIL THIS PAGE TO A FRIEND

PloS one

Characterization of the loss of SUMO pathway function on cancer cells and tumor proliferation.


PMID 25860128

Abstract

SUMOylation is a post-translational ubiquitin-like protein modification pathway that regulates important cellular processes including chromosome structure, kinetochore function, chromosome segregation, nuclear and sub-nuclear organization, transcription and DNA damage repair. There is increasing evidence that the SUMO pathway is dysregulated in cancer, raising the possibility that modulation of this pathway may have therapeutic potential. To investigate the importance of the SUMO pathway in the context of cancer cell proliferation and tumor growth, we applied lentivirus-based short hairpin RNAs (shRNA) to knockdown SUMO pathway genes in human cancer cells. shRNAs for SAE2 and UBC9 reduced SUMO conjugation activity and inhibited proliferation of human cancer cells. To expand upon these observations, we generated doxycycline inducible conditional shRNA cell lines for SAE2 to achieve acute and reversible SAE2 knockdown. Conditional SAE2 knockdown in U2OS and HCT116 cells slowed cell growth in vitro, and SAE2 knockdown induced multiple terminal outcomes including apoptosis, endoreduplication and senescence. Multinucleated cells became senescent and stained positive for the senescence marker, SA-β Gal, and displayed elevated levels of p53 and p21. In an attempt to explain these phenotypes, we confirmed that loss of SUMO pathway activity leads to a loss of SUMOylated Topoisomerase IIα and the appearance of chromatin bridges which can impair proper cytokinesis and lead to multinucleation. Furthermore, knockdown of SAE2 induces disruption of PML nuclear bodies which may further promote apoptosis or senescence. In an in vivo HCT116 xenograft tumor model, conditional SAE2 knockdown strongly impaired tumor growth. These data demonstrate that the SUMO pathway is required for cancer cell proliferation in vitro and tumor growth in vivo, implicating the SUMO pathway as a potential cancer therapeutic target.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB4502593
Anti-CTIP antibody produced in rabbit, affinity isolated antibody
SAB2101954
Anti-RBBP8 antibody produced in rabbit, affinity isolated antibody
SAB2105764
Anti-RBBP8 antibody produced in rabbit, affinity isolated antibody
SAB3500491
Anti-RBBP8 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB4502594
Anti-RBBP8 antibody produced in rabbit, affinity isolated antibody
HPA039890 Anti-RBBP8 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB3500487
Anti-SAE2 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB1300514
Anti-UBA2 (C-term A600) antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
SAB1300513
Anti-UBA2 (C-term E616) antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
SAB1300146
Anti-UBA2 (N-term) antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
SAB1400373
Anti-UBA2 antibody produced in mouse, IgG fraction of antiserum, buffered aqueous solution
HPA041436
Anti-UBA2 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB4500027
Anti-UBA2, C-Terminal antibody produced in rabbit, affinity isolated antibody
EHU109721 MISSION® esiRNA, esiRNA human UBA2 (esiRNA1)
EHU070611 MISSION® esiRNA, esiRNA human RBBP8 (esiRNA1)
EMU092131 MISSION® esiRNA, esiRNA targeting mouse Ube2i (esiRNA1)
EMU078421 MISSION® esiRNA, esiRNA targeting mouse Uba2 (esiRNA1)
SAB2702168
Monoclonal Anti-RBBP8 antibody produced in mouse
PLA0112
Rabbit anti-CtIP Antibody, Affinity Purified, Powered by Bethyl Laboratories, Inc.